FOXO3 and neoplasm: These studies indicate that down regulation of drug transporters during co-treatment (UroA/UAS03 + 5FU) enable effective elimination of 5FUR cancer cells potentially through FOXO3-FOXM1 signaling leading to reduced tumor size.